This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Jan 19;376(3):280-282.

doi: 10.1056/NEJMe1614717. Epub 2016 Dec 21.

B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis

Peter A Calabresi¹

Affiliations

PMID: 28001486
DOI: 10.1056/NEJMe1614717

Editorial

B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis

Peter A Calabresi. N Engl J Med. 2017.

. 2017 Jan 19;376(3):280-282.

doi: 10.1056/NEJMe1614717. Epub 2016 Dec 21.

Author

Peter A Calabresi¹

Affiliation

¹ From the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore.

PMID: 28001486
DOI: 10.1056/NEJMe1614717

No abstract available

PubMed Disclaimer

Comment on

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Clinical Trial.

Similar articles

Treatment of multiple sclerosis with anti-CD20 antibodies.
Barun B, Bar-Or A. Barun B, et al. Clin Immunol. 2012 Jan;142(1):31-7. doi: 10.1016/j.clim.2011.04.005. Epub 2011 Apr 15. Clin Immunol. 2012. PMID: 21555250 Review.
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
Gasperini C, Haggiag S, Ruggieri S. Gasperini C, et al. Expert Opin Investig Drugs. 2013 Oct;22(10):1243-53. doi: 10.1517/13543784.2013.820275. Epub 2013 Jul 16. Expert Opin Investig Drugs. 2013. PMID: 23855792 Review.
CD20-targeted therapy: the next generation of antibodies.
van Meerten T, Hagenbeek A. van Meerten T, et al. Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007. Semin Hematol. 2010. PMID: 20350667 Review.
B cell depletion in the treatment of multiple sclerosis.
Myhr KM, Torkildsen Ø, Lossius A, Bø L, Holmøy T. Myhr KM, et al. Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23. Expert Opin Biol Ther. 2019. PMID: 30632834 Review.
B cell-directed therapies in multiple sclerosis.
Gasperi C, Stüve O, Hemmer B. Gasperi C, et al. Neurodegener Dis Manag. 2016;6(1):37-47. doi: 10.2217/nmt.15.67. Neurodegener Dis Manag. 2016. PMID: 26782316 Review.

See all similar articles

Cited by

Monoclonal Antibodies in Multiple Sclerosis: Present and Future.
Voge NV, Alvarez E. Voge NV, et al. Biomedicines. 2019 Mar 14;7(1):20. doi: 10.3390/biomedicines7010020. Biomedicines. 2019. PMID: 30875812 Free PMC article. Review.
MicroRNAs: Roles in Regulating Neuroinflammation.
Gaudet AD, Fonken LK, Watkins LR, Nelson RJ, Popovich PG. Gaudet AD, et al. Neuroscientist. 2018 Jun;24(3):221-245. doi: 10.1177/1073858417721150. Epub 2017 Jul 24. Neuroscientist. 2018. PMID: 28737113 Free PMC article.
Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?
Tsitokana ME, Lafon PA, Prézeau L, Pin JP, Rondard P. Tsitokana ME, et al. Int J Mol Sci. 2023 Jan 30;24(3):2632. doi: 10.3390/ijms24032632. Int J Mol Sci. 2023. PMID: 36768953 Free PMC article. Review.
CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.
Bunse M, Pfeilschifter J, Bluhm J, Zschummel M, Joedicke JJ, Wirges A, Stark H, Kretschmer V, Chmielewski M, Uckert W, Abken H, Westermann J, Rehm A, Höpken UE. Bunse M, et al. Nat Commun. 2021 Jan 11;12(1):240. doi: 10.1038/s41467-020-20488-3. Nat Commun. 2021. PMID: 33431832 Free PMC article.
Can ad hoc analyses of clinical trials help personalize treatment decisions?
Biltaji E, Kumar SS, Enioutina EY, Sherwin CMT. Biltaji E, et al. Br J Clin Pharmacol. 2017 Nov;83(11):2337-2338. doi: 10.1111/bcp.13377. Epub 2017 Aug 16. Br J Clin Pharmacol. 2017. PMID: 28815756 Free PMC article. No abstract available.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations